Dendritic cells from induced pluripotent stem cells with an adult phenotype for immunotherapy

Applications: Cancers, cell therapy, immunotherapy

Dendritic cells derived from induced pluripotent stem (iPS) cells with conventional methods have been shown to display a primitive or ‘fetal’ phenotype, which does not stimulate the immune system effectively, limiting their therapeutic ability. Oxford’s technology provides a solution to the existing problem having the following features and benefits.

Features	Benefits
A simple method of generating DCs which displays a mature ‘adult’ phenotype through exploitation of the epigenetic memory.	Enables the scalable production of DCs that display a mature ‘adult’ phenotype from iPS cells.
DCs derived from this novel approach demonstrate combined functionality of primary DCs together with the many advantages of being derived from a pluripotent source.	Ability to scale-up procedures, tractability for genome editing and availability of otherwise inaccessible subsets of DCs with desirable properties.
DCs displaying an adult phenotype are suitable for applications in a variety of indications.	Including cancer immunotherapy, vaccination against chronic infectious microorganisms, and the induction of tolerance to defined protein antigens.

Patented and available for:

Licensing
Co-development
Consulting

Request more information
about this technology

Back to Technologies Available

Technologies for License

Dendritic cells from induced pluripotent stem cells with an adult phenotype for immunotherapy

Ready to get in touch?